![Mike Imhof](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Network origin in Mike Imhof first degree
Entity | Entity type | Industry | |
---|---|---|---|
Sensimed SA
![]() Sensimed SA Medical SpecialtiesHealth Technology Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.
4
| Subsidiary | Medical Specialties | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Mike Imhof via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor | |
BASF Pharma Ltd.
![]() BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Pharmaceuticals: Major | Founder | |
The Hebrew University of Jerusalem | College/University | Undergraduate Degree | |
Immatics Biotechnologies GmbH
![]() Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Director/Board Member | |
Ruprecht-Karls-Universität Heidelberg | College/University | Director/Board Member | |
University of Lausanne | College/University | Graduate Degree | |
SYMETIS SA | Biotechnology | Director/Board Member | |
SUPERSONIC IMAGINE | Medical Specialties | Director/Board Member | |
Evolva SA
![]() Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Miscellaneous Commercial Services | Chairman | |
Agate RM Investments & Medical Technologies Ltd.
![]() Agate RM Investments & Medical Technologies Ltd. Investment ManagersFinance Agate RM Investments & Medical Technologies Ltd. (Agate) is a venture capital firm founded in 2007 by Dani Naveh. The firm is headquartered in Tel Aviv, Israel. | Investment Managers | Director of Finance/CFO | |
EPITOMEE MEDICAL LTD | Pharmaceuticals: Major | Director/Board Member | |
MST Medical Surgery Technologies Ltd.
![]() MST Medical Surgery Technologies Ltd. Medical SpecialtiesHealth Technology MST Medical Surgery Technologies Ltd. develops image guided solutions for laparoscopy. Its product AutoLap, an image-based laparoscope positioning system for minimally invasive surgical procedures. The firm offers the surgeon full and natural control of the laparoscope and exceptional intraoperative image capabilities and the freedom to fully focus on the surgical procedure. The company was founded by Ziv Tamir and Moti Sholev in 2005 and is headquartered in Yokneam, Israel. | Medical Specialties | Director/Board Member | |
RDD Pharma Ltd.
![]() RDD Pharma Ltd. Medical SpecialtiesHealth Technology RDD Pharma Ltd. develops pharmacological treatments for diseases of the anorectal region. The company was founded by Nir Barak in 2008 and is headquartered in Ramat Hachayal, Israel. | Medical Specialties | Director/Board Member | |
EVOLVA HOLDING SA | Food: Specialty/Candy | Chairman | |
Zentralinstitut für Seelische Gesundheit | Director/Board Member | ||
Swiss Health Observatory | Corporate Officer/Principal | ||
Ono Academic College | College/University | Graduate Degree | |
NBE-Therapeutics AG
![]() NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Chairman | |
ISCARE as (Czech Republic)
![]() ISCARE as (Czech Republic) Medical/Nursing ServicesHealth Services Iscare I.V.F. as provides health-care services in the fields of assisted reproduction, complex treatment of obesity, gastroenterology and treatment of idiopathic intestinal inflammations and plastic surgery. The company was founded in 1994 and is headquartered in Jankovcova, Czech Republic. | Medical/Nursing Services | Director/Board Member | |
ImevaX GmbH
![]() ImevaX GmbH BiotechnologyHealth Technology ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member | |
Immatics US, Inc.
![]() Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Director/Board Member | |
Clew Medical Ltd.
![]() Clew Medical Ltd. Internet Software/ServicesTechnology Services Clew Medical Ltd. provides healthcare providers and administrators with high-accuracy predictive clinical analytics. It focuses on big data and real time analytics in healthcare and provide a set of services for care givers, nurses, physicians, and administrators. The company was founded by Gal Salmon and is headquartered in Netanya, Israel. | Internet Software/Services | Director/Board Member | |
270 Surgical Ltd.
![]() 270 Surgical Ltd. Medical/Nursing ServicesHealth Services 270 Surgical Ltd. engages in provision of specialty laparoscopic system for wide cavity visualization. The company was founded by Avi Levyin 2016 and is headquartered in Netanya, Israel. | Medical/Nursing Services | Director/Board Member | |
Clal Factoring & Finance Ltd. | Corporate Officer/Principal | ||
Incede Labs | Founder |
Statistics
International
Israel | 12 |
Germany | 8 |
Switzerland | 7 |
United Kingdom | 2 |
France | 2 |
Sectoral
Health Technology | 13 |
Consumer Services | 5 |
Finance | 3 |
Commercial Services | 3 |
Health Services | 3 |
Operational
Director/Board Member | 21 |
Corporate Officer/Principal | 7 |
Chairman | 4 |
Founder | 3 |
Private Equity Investor | 2 |
Most connected contacts
Insiders | |
---|---|
Erich Schlick | 15 |
Ariel Moses | 13 |
Sacha Cerboni | 3 |
David Bailey | 1 |
- Stock Market
- Insiders
- Mike Imhof
- Company connections